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mutations in the SHR that do not impact on the molecular weight of the native
protein, but may affect its post-translational modification (PTM). This notion
is supported by additional data, which suggest an alteration in 
 
O
 
-linked -N-
acetylglucosamination. 
 
Conclusion:
 
 Our results emphasize the role of the SHR Cd36 gene defect
as the factor underlying its cardiac restricted LCFA utilization. The functional
impact of this gene defect includes alterations in CD36 protein level and sus-
ceptibility to PTM.
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Introduction:
 
 Thrombi in contact with non re-endothelialized stent struts
associated with drug-eluting stent (DES) thrombosis. Hence, detection of
thrombi in DES could help to evaluate the risk of DES thrombosis. Annexin
V radio-labelled with 99mTechnetium (99mTc) is a radio-tracer with a high
affinity for activated platelets.
 
Objectives:
 
 Our objectives were: 1) to develop an animal model of non-
occlusive thrombosis of stents, 2) to evaluate the ability of annexin V 99mTc
for the detection of in-stent thrombi using scintigraphy. 
 
Methods:
 
 Right carotid arteries of NZW rabbits (n = 14) fed a high cho-
lesterol diet were implanted with overlapping DES (n = 7) or bare-metal
stents (BMS; n = 7). Four weeks after stent implantation, rabbits underwent
a first scintigraphy 3 hours after injection of 200 MBq of radio-labelled
annexin V 99mTc. At the end of the first scintigraphy, a suture was placed
surgically proximal to the stented carotid arteries in order to induce a
thrombus-prone flow limiting stenosis. Four days later, a second scintig-
raphy was performed. After the second scintigraphy, stents were excised,
imaged ex vivo and then fixed for histological examination and scanning
electron microscopy (SEM). 
 
Results:
 
 Activities measured in vivo in the stented carotid arteries after injec-
tion of annexin V 99mTc were higher on the second scintigraphy after creation
of a surgical stenosis as compared to the first scintigraphy (0.24 vs. 0.15 counts/
pixel/ MBq, respectively; p<0.05). On the second scintigraphy, activities were
higher in DES vs. BMS (0.26 vs. 0.19 counts/pixel/ MBq, respectively;
p < 0.005). High activities measured in stents in vivo were associated with the
detection of thrombi on corresponding histological sections and SEM.
 
Conclusions:
 
 In this work, we developed a rabbit model of non-occlusive
thrombosis of stents in carotid arteries. In this model, in-stent thrombi could
be detected using annexin V 99mTc scintigraphy.
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Aim: Glutamine is the most abundant amino acid in the plasma, and has
been shown to exert cardioprotective effects. However, the underlying mech-
anisms remained unclear, but may include an anaplerotic effect via its meta-
bolic conversion to citric acid cycle (CAC) intermediates or activation of the
hexosamine biosynthetic pathway (HBP). 
Methods: To assess the potential roles of these mechanisms, we evaluated
the metabolic effects of a physiologically relevant concentration of glutamine
(0.5mM) in isolated working rat hearts perfused with 13C-labeled substrates
with or without 20 M azaserine (an HBP inhibitor) and under restricted supply
of carbohydrates (CHO, i.e. without pyruvate/insulin). 
Results: When perfused with a mixture of CHOs, a fatty acid oleate and
insulin (controls), the addition of glutamine had no effect on functional
parameters except for a 17% (p<0.05) decrease in relaxation. However it
resulted in an increase in the percent contribution of 13C-oleate to acetyl-
CoA production (51%) and triglyceride formation (2.8 folds). This was
accompanied by a significant reduction (p>0.05) tissue levels of the CAC
intermediates (in nmol/gww): citrate: 260±10 vs. 222±6 and malate 128±5
vs. 103±3 . Inhibition of HBP with azaserine restored oleate oxidation and
tissue CAC levels, but not triglyceride formation. When perfused under
restricted supply of CHOs, hearts displayed significantly decreased cardiac
output (65%), a greater percent contribution of glucose to pyruvate forma-
tion (60%), and lower tissue citrate and malate levels (45%). Addition of
glutamine restored cardiac output and glucose contribution to pyruvate for-
mation but not tissue CAC levels. 
Conclusion: Collectively, these results demonstrate the capacity of
glutamine to modulate energy substrate selection and function in the perfused
heart. Furthermore, the potential mechanisms underlying these effects appear
to be mediated via the HBP rather than anaplerosis.
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Background: Aspirin resistance has been widely reported but the under-
lying mechanisms remain unclear. Previous studies have suggested a relation-
ship between accelerated platelet turn-over and aspirin resistance in patients
with coronary artery disease. The purpose of this study was to determine
whether aspirin resistance could be linked to accelerated platetet turn-over.
Methods: We performed a prospective monocentric study including 50
consecutive patients with stable coronary artery disease treated by aspirin (75
to 250 mg/day) without any other antiaggregant treatment. Aspirin resistance
was characterized 24 hours after aspirin intake by light transmission aggrego-
metry using 0.5 mg/mL arachidonic acid. Aspirin resistance was defined as
>20% residual agregation. Platelet turn-over was estimated at the same time
by measurement of mean platelet volume, % of reticulated platelets, serum P-
selectin, platelet P-selectin and serum thrombopoietin.
Results: Among 50 patients (70±11 y.o. mean±1,5, 76% male, 52% type 2
diabetes mellitus, 16% active smokers), 18 (36%) were identified as aspirin
resistants. Table 1 shows the mean value of markers currently linked to
platelet turn-over depending on the presence of aspirin resistance. Serum
thrombopoietin was significantly increased in patients with aspirin resistance
compared to patients with no aspirin resistance. No statistical difference was
demonstrated for mean platelet volume, reticulated platelets, platelet P-selectin
and serum P-selectin. Serum thrombopoietin values were not correlated with
other platelet turn-over parameters. There was no significant correlation
between serum thrombopoietin and inflammatory markers.
Conclusion: Serum thrombopoietin is associated with aspirin resistance,
but no other parameters currently linked to platelet turn-over. Further studies
are needed to determine whether serum thrombopoietin can predict aspirin
resistance in a larger cohort.
